EMA validates Type II variation application for enfortumab vedotin with pembrolizumab for treatment of bladder cancer

Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival

Merck’s Keytruda reduced the risk of death by 38% for patients with RCC

Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC

Indian Red Cross Society and Cadila to launch training of 50,000 students for CPR and First Aid

The initiative is a response to the rising incidents of heart attacks and cardiac arrests in the state

Zydus receives USFDA’s final approval for Gabapentin Tablets, 300 mg and 600 mg

Gabapentin is indicated for the management of Postherpetic Neuraligia

Laurus Labs inks JV agreement with KRKA, Slovenia

The registered capital of the newly founded company is € 50 million

Syngene Q3 FY 24 PAT up 4% to Rs 115 Cr

For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)

Lily announces positive gene therapy result for genetic hearing loss

Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant

BenevolentAI appoints former Bayer R&D head Dr. Joerg Moeller as CEO

An accomplished R&D leader and champion of the application of AI to drug discovery

ImmunoBrain Checkpoint appoints Dr. Sanjay Keswani as CEO

He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom

Lupin receives tentative USFDA approval for Rivaroxaban Tablets USP